Antimuscarinics, β-3 Agonists, and Phosphodiesterase Inhibitors in the Treatment of Male Lower Urinary Tract Symptoms: An Evolving Paradigm (Q38913912)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Antimuscarinics, β-3 Agonists, and Phosphodiesterase Inhibitors in the Treatment of Male Lower Urinary Tract Symptoms: An Evolving Paradigm	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

1 reference

Europe PubMed Central

Antimuscarinics, β-3 Agonists, and Phosphodiesterase Inhibitors in the Treatment of Male Lower Urinary Tract Symptoms: An Evolving Paradigm (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

author name string

Nadir I Osman

1

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Reem Aldamanhori

2

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Altaf Mangera

3

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Christopher R Chapple

4

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

publication date

1 August 2016

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Urologic Clinics of North America

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

43

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

337-349

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Signal transduction underlying carbachol-induced contraction of human urinary bladder

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

The urothelium in overactive bladder: passive bystander or active participant?

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Non-neuronal cholinergic system in human bladder urothelium

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: pathophysiology and pharmacotherapy of overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Model of peripheral autonomous modules and a myovesical plexus in normal and overactive bladder function

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Purinergic and muscarinic modulation of ATP release from the urothelium and its paracrine actions

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Muscarinic receptors in the bladder: from basic research to therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

M(3) muscarinic receptors mediate contraction of human urinary bladder

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Clinical Efficacy, Safety, and Tolerability of Once-Daily Fesoterodine in Subjects with Overactive Bladder

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Tolterodine--a new bladder-selective antimuscarinic agent

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Clinical pharmacokinetics of trospium chloride

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Actions of two main metabolites of propiverine (M-1 and M-2) on voltage-dependent L-type Ca2+ currents and Ca2+ transients in murine urinary bladder myocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Symptom change after discontinuation of successful antimuscarinic treatment in patients with overactive bladder symptoms: a randomised, multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events?

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Urinary bladder contraction and relaxation: physiology and pathophysiology

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Beta3-adrenoceptors in human detrusor muscle

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Nitric oxide/cGMP-mediated effects in the outflow region of the lower urinary tract--is there a basis for pharmacological targeting of cGMP?

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Signalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Characterization and functional role of androgen-dependent PDE5 activity in the bladder

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Urodynamic improvements following oral medical therapy for partial bladder outlet obstruction in an animal model.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Effects of the phosphodiesterase 5 inhibitor Tadalafil on bladder function in a rat model of partial bladder outlet obstruction.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Nitric oxide/cyclic guanosine monophosphate signalling mediates an inhibitory action on sensory pathways of the micturition reflex in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Effect of a single treatment with tadalafil on blood flow in lower urinary tract tissues in rat models of bladder overdistension/emptying and abdominal aorta clamping/release.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Sildenafil influences lower urinary tract symptoms.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Efficacy and safety of tadalafil monotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Comparative effectiveness of oral drug therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Proportion of tadalafil-treated patients with clinically meaningful improvement in lower urinary tract symptoms associated with benign prostatic hyperplasia – integrated data from 1,499 study participants

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Tadalafil 5 mg once daily for the treatment of Asian men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: analyses of data pooled from three randomized, double-blind, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Effects of tadalafil on nighttime voiding (nocturia) in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a post hoc analysis of pooled data from four randomized, placebo-controlled clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2016.04.004

7 January 2021

Identifiers

10.1016/J.UCL.2016.04.004

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38913912&oldid=2088708315"